Aperio Group’s Heron Therapeutics HRTX Stock Holding History

Aperio Group’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$271K	Buy	12,801 +1,244	+11%	+$21.6K	﹤0.01%	2221
2020 Q3	$171K	Buy	+11,557	New	+$180K	﹤0.01%	2257
2020 Q1	–	Sell	-9,933	Closed	-$233K	–	2370
2019 Q4	$233K	Buy	+9,933	New	+$220K	﹤0.01%	2149
2019 Q3	–	Sell	-8,205	Closed	-$153K	–	2513
2019 Q2	$153K	Sell	8,205 -1,584	-16%	-$31.6K	﹤0.01%	2265
2019 Q1	$239K	Sell	9,789 -2,096	-18%	-$54.9K	﹤0.01%	2094
2018 Q4	$308K	Sell	11,885 -1,828	-13%	-$50.3K	﹤0.01%	1928
2018 Q3	$434K	Buy	13,713 +2,452	+22%	+$91.3K	﹤0.01%	1842
2018 Q2	$437K	Buy	11,261 +1,416	+14%	+$45.1K	﹤0.01%	1807
2018 Q1	$272K	Buy	+9,845	New	+$223K	﹤0.01%	1997

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Aperio Group's HRTX Position: Q4 2020 in Review

Aperio Group increased its Heron Therapeutics (HRTX) stake by 11% in Q4 2020, buying an estimated $21.6K and bringing the position to 12,801 shares worth $271K. The position accounts for ﹤0.01% of the portfolio, ranked #2221.

Aperio Group first reported a position in HRTX in Q1 2018 and has held it in 9 quarters since. The position peaked at $437K in Q2 2018. 189 funds tracked by Wall St. Rank hold HRTX as of Q4 2020.

Aperio Group held 12,801 shares of Heron Therapeutics worth $271K as of Q4 2020.
Aperio Group bought 1,244 Heron Therapeutics shares in Q4 2020, an estimated $21.6K.
Heron Therapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2221 holding.
Aperio Group first reported a position in Heron Therapeutics in Q1 2018 and has held it in 9 quarters since.
Aperio Group's Heron Therapeutics position peaked at $437K in Q2 2018.
189 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.